Friday 20 September 2013

US FDA grants breakthrough therapy designation to Boehringer Ingelheim’s volasertib to treat patients with AML « New Drug Approvals

US FDA grants breakthrough therapy designation to Boehringer Ingelheim’s volasertib to treat patients with AML « New Drug Approvals:

'via Blog this'

No comments:

Post a Comment